Choksi Laboratories Submits Q4FY26 Compliance Certificate Under SEBI Regulation 74(5)

1 min read     Updated on 07 Apr 2026, 08:41 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Choksi Laboratories Limited submitted its Q4FY26 compliance certificate under SEBI Regulation 74(5) to BSE Limited on 07-04-2026. The certificate, issued by registrar MUFG Intime India Private Limited, confirms proper handling of securities dematerialisation processes during the quarter ended 31st March 2026. The submission demonstrates the company's adherence to regulatory requirements for depository participant processes and securities handling.

powered bylight_fuzz_icon
37120315

*this image is generated using AI for illustrative purposes only.

Choksi laboratories Limited has submitted its compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulation 2018 for the quarter ended 31st March 2026. The pharmaceutical company filed the mandatory certificate with BSE Limited on 07-04-2026, ensuring adherence to regulatory requirements for securities dematerialisation processes.

Regulatory Compliance Details

The compliance certificate was issued by MUFG Intime India Private Limited (formerly Link Intime India Private Limited), which serves as the company's registrar and share transfer agent. The certificate confirms that all securities received from depository participants for dematerialisation during Q4FY26 were properly processed within prescribed timelines.

Parameter: Details
Quarter Covered: Q4FY26 (ended 31st March 2026)
Filing Date: 07-04-2026
Registrar: MUFG Intime India Private Limited
Certificate Date: April 3, 2026
Script Code: 526546

Certificate Confirmation

MUFG Intime India confirmed that securities received from depository participants during the quarter were appropriately accepted or rejected to the depositories. The registrar verified that all security certificates received for dematerialisation were properly mutilated and cancelled after due verification by depository participants.

Key confirmations included in the certificate:

  • Securities were confirmed to depositories within prescribed timelines
  • Security certificates comprised in dematerialisation were listed on relevant stock exchanges
  • Names of depositories were substituted in the register of members as registered owners
  • All processes followed regulatory guidelines for dematerialisation

Corporate Information

Choksi Laboratories Limited operates from its corporate office and central laboratory located at Survey No 9/1, Near Tulsiyana Industrial Park, Gram Kumerdi, Indore. The company secretary and compliance officer Prakhar Dubey signed the submission to BSE Limited, ensuring proper documentation of the regulatory compliance.

The submission reflects the company's commitment to maintaining transparency and adhering to SEBI regulations governing depositories and participants. This quarterly compliance certificate is a mandatory requirement under SEBI regulations to ensure proper handling of securities dematerialisation processes.

Historical Stock Returns for Choksi Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
+3.21%-5.41%+2.03%-46.75%-13.27%+1,211.91%

How might the transition from Link Intime to MUFG Intime India impact Choksi Laboratories' future share transfer operations and costs?

What potential business developments could Choksi Laboratories announce in their upcoming Q4FY26 earnings report following this compliance filing?

Will SEBI introduce any new regulatory changes for depositories that could affect pharmaceutical companies' compliance requirements in FY27?

Choksi Laboratories Publishes Postal Ballot Notice for Director Appointment

2 min read     Updated on 27 Mar 2026, 06:31 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Choksi Laboratories Limited has completed newspaper publication requirements for its postal ballot notice regarding the appointment of Mr. Ritik Pavecha as Non-Executive Independent Director. The company published confirmation in Free Press Journal and Choutha Sansar on March 27, 2026, with e-voting scheduled from March 28 to April 26, 2026.

powered bylight_fuzz_icon
36072156

*this image is generated using AI for illustrative purposes only.

Choksi Laboratories Limited has issued a postal ballot notice dated February 7, 2026, seeking shareholder approval through e-voting for the appointment of Mr. Ritik Pavecha as Non-Executive Independent Director. The notice was submitted to BSE Limited on March 26, 2026, in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Newspaper Publication Compliance

Following regulatory requirements, the company published confirmation of postal ballot notice dispatch in newspapers on March 27, 2026. The publication appeared in both English and Hindi editions to ensure comprehensive shareholder communication:

Publication Details: Information
Publication Date: March 27, 2026
English Edition: Free Press Journal
Hindi Edition: Choutha Sansar
Purpose: Postal ballot dispatch confirmation and e-voting information

Key Voting Details

The postal ballot process follows a structured timeline with specific dates for shareholder participation:

Parameter: Details
Cut-off Date: Friday, March 20, 2026
E-voting Commencement: Saturday, March 28, 2026 at 09:00 a.m. (IST)
E-voting End: Sunday, April 26, 2026 at 05:00 p.m. (IST)
Result Declaration: On or before April 28, 2026

Director Appointment Proposal

The special resolution seeks approval for the appointment of Mr. Ritik Pavecha (DIN: 08790431) as Non-Executive Independent Director for a term of 5 consecutive years commencing from February 7, 2026. The Board of Directors appointed him as Additional Independent Director on February 7, 2026, subject to shareholder confirmation.

Candidate Profile

Details: Information
Name: Mr. Ritik Pavecha
DIN: 08790431
Date of Birth: March 18, 1994
Qualification: Bachelor of Commerce, Company Secretary
Experience: Audit and Assurance Services, Corporate Compliance
Current Shareholding: Nil

Governance and Compliance

The company has appointed Ms. Surabhi Agrawal, FCS (COP.: 23696), Proprietor of M/s. Surabhi Agrawal & Associates, as the scrutinizer to conduct the postal ballot process. Central Depository Services (India) Limited (CDSL) has been engaged as the authorized agency for providing e-voting facility to shareholders.

In accordance with MCA circulars and SEBI regulations, the postal ballot notice is being sent only through electronic mode to shareholders whose email addresses are registered with the company, depositories, or Registrar and Transfer Agent. The notice is available on the company's website, BSE website, and CDSL's e-voting platform.

Voting Process

Shareholders holding shares in both physical and dematerialized form as on the cut-off date of March 20, 2026, are entitled to vote through the remote e-voting facility. The voting can be conducted through CDSL/NSDL e-voting system for individual shareholders in demat mode, CDSL e-voting system for physical shareholders and non-individual shareholders, and direct access through depository participant platforms.

Once votes are cast, shareholders will not be allowed to modify their voting decisions. The voting rights will be proportionate to the paid-up equity share capital held as on the cut-off date. Results will be communicated to stock exchanges and displayed on the company website upon completion of the scrutiny process.

Historical Stock Returns for Choksi Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
+3.21%-5.41%+2.03%-46.75%-13.27%+1,211.91%

What strategic initiatives or business expansion plans might Choksi Laboratories be considering that require additional independent board expertise?

How could Mr. Pavecha's audit and compliance background influence the company's governance practices and regulatory strategy over the next five years?

Will Choksi Laboratories likely seek additional board appointments or restructuring following this independent director addition?

More News on Choksi Laboratories

1 Year Returns:-13.27%